Loading…
Kymera Therapeutics, Inc. is projected to rise to $131.87 by 2027, a +23% move from its current price of $107.01. KYMR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $104.13 | $107.05 | $110.05 | +0.03% |
| Aug 2 | $102.98 | $107.08 | $111.35 | +0.07% |
| Aug 3 | $102.12 | $107.12 | $112.37 | +0.10% |
| Aug 4 | $101.40 | $107.16 | $113.24 | +0.14% |
| Aug 5 | $100.77 | $107.19 | $114.02 | +0.17% |
| Aug 6 | $100.21 | $107.23 | $114.74 | +0.21% |
| Aug 7 | $99.71 | $107.27 | $115.40 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $99.71 | $107.27 | $115.40 | +0.24% |
| Week 2 | $96.97 | $107.53 | $119.23 | +0.48% |
| Week 3 | $94.97 | $107.78 | $122.33 | +0.72% |
| Week 4 | $93.35 | $108.04 | $125.05 | +0.97% |
| Week 5 | $91.97 | $108.30 | $127.53 | +1.21% |
| Week 6 | $90.77 | $108.56 | $129.85 | +1.45% |
| Week 7 | $89.69 | $108.83 | $132.04 | +1.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc.
was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc. (KYMR) currently trades at $110.34 with a market cap of $9.08B and is ranked 932. The stock sits in the healthcare sector as a clinical-stage biopharmaceutical company focused on selective protein degradation therapies.
A major floor 33.4% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
The nearest ceiling, 11.5% above — a clean break opens room to run.
A major ceiling 26.0% above — clearing it would confirm fresh momentum.
Key KYMR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYMR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $107.81 | Sell | $107.65 | Sell |
| MA 10 | $110.00 | Sell | $109.17 | Sell |
| MA 20 | $112.53 | Sell | $108.87 | Sell |
| MA 50 | $97.56 | Buy | $101.63 | Buy |
| MA 100 | $90.48 | Buy | $93.47 | Buy |
| MA 200 | $81.95 | Buy | $82.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.60 | Neutral |
| Stoch RSI (14) | 17.12 | Buy |
| CCI (20) | -115.02 | Sell |
| Williams %R (14) | -83.27 | Info |
| MACD (12,26,9) | -1.97 | Sell |
| ROC (12) | -4.52 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 16.73 | Buy |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 0.94 | Buy |
| Ultimate (7,14,28) | 28.19 | Buy |
| Momentum (10) | -6.98 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 105.38 | Buy |
| ADX (14) | 19.83 | Neutral |
| ATR (14) | 2.44 | Info |
Technically, the sentiment is BULLISH, with RSI(14) at 50 and the 50-day simple moving average at $94.56 versus the 200-day simple moving average at $80.42. The near-term framework shows support at $76.91 and resistance at $119.35. The 30-day price range spans from $89.46 to $136.09, giving a defined near-term trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $68.14 | $107.01 | $139.77 | 0% | Neutral | |
| $105.05 | $131.87 | $175.10 | +23% | Bullish | |
| $117.54 | $151.84 | $209.40 | +42% | Bullish | |
| $134.74 | $178.21 | $253.13 | +67% | Bullish | |
| $162.35 | $219.25 | $319.23 | +105% | Bullish | |
| $194.98 | $268.35 | $399.25 | +151% | Bullish | |
| $234.99 | $329.17 | $499.29 | +208% | Bullish | |
| $247.63 | $352.66 | $544.35 | +230% | Bullish | |
| $250.34 | $362.16 | $568.08 | +238% | Bullish | |
| $284.15 | $417.29 | $664.39 | +290% | Bullish | |
| $476.54 | $749.19 | $1,269.66 | +600% | Bullish | |
| $790.63 | $1,397.86 | $2,594.12 | +12.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $68.14 | $107.01 | $124.91 | +0.00% |
| August 2026 | $94.50 | $110.94 | $133.29 | +3.67% |
| September 2026 | $93.26 | $110.41 | $134.47 | -0.47% |
| October 2026 | $90.54 | $107.91 | $132.84 | -2.26% |
| November 2026 | $91.44 | $109.60 | $136.09 | +1.57% |
| December 2026 | $92.71 | $111.70 | $139.77 | +1.91% |
Click any year to see its month-by-month KYMR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KYMR to range from $68.14 to $139.77 through 2026. The $107.01 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The KYMR price prediction for 2027 points to an average of $131.87 (low $105.05, high $175.10) — a potential gain of +23% on today's $107.01. Buyers look set to stay in control over this stretch.
In 2028, KYMR is projected to trade between $117.54 and $209.40, averaging $151.84 — a potential gain of +42% from today's $107.01. That is up +15% on the projected 2027 average. Momentum favours further upside here.
Kymera Therapeutics, Inc.'s 2029 outlook centres on $178.21, within a $134.74 to $253.13 range. That is up +17% on the projected 2028 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, KYMR could reach as high as $319.23, with a base case around $219.25 and support toward $162.35 — roughly +105% from $107.01. Momentum favours further upside here.
Expect KYMR to range from $194.98 to $399.25 through 2031. The $268.35 average target implies a +151% move from current prices. That is up +22% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The KYMR price prediction for 2032 points to an average of $329.17 (low $234.99, high $499.29) — a potential gain of +208% on today's $107.01. Momentum favours further upside here.
In 2033, KYMR is projected to trade between $247.63 and $544.35, averaging $352.66 — a potential gain of +230% from today's $107.01. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Kymera Therapeutics, Inc.'s 2034 outlook centres on $362.16, within a $250.34 to $568.08 range. That is up +3% on the projected 2033 average. That marks a +238% change versus current levels. Momentum favours further upside here.
By 2035, KYMR could reach as high as $664.39, with a base case around $417.29 and support toward $284.15 — roughly +290% from $107.01. Buyers look set to stay in control over this stretch.
Expect KYMR to range from $476.54 to $1,269.66 through 2040. The $749.19 average target implies a +600% move from current prices. That is up +80% on the projected 2035 average. Momentum favours further upside here.
The KYMR price prediction for 2050 points to an average of $1,397.86 (low $790.63, high $2,594.12) — a potential gain of +12.1x on today's $107.01. Buyers look set to stay in control over this stretch.
Investing $1,000 in KYMR today (≈ 9.344921 KYMR) could be worth
$13,062.93
+$12,062.93 (+1206%) by 2050 · US Dollar
Based on the average projected KYMR price of $1,397.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYMRwould be worth at today's price.
$1,000 invested in KYMR on Jul 30, 2025 (≈ 22.691173 KYMR) would be worth
$2,428.18
+$1,428.18 (+142.8%) today · 2.43× · US Dollar
Based on a KYMR entry price of $44.07 vs. today's $107.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $110.38 | $969.47 | -3.1% |
| 1 month ago | $114.67 | $933.2 | -6.7% |
| 3 months ago | $80.71 | $1,325.86 | +32.6% |
| 6 months ago | $72.69 | $1,472.14 | +47.2% |
| 1 year ago | $44.07 | $2,428.18 | +142.8% |
| All time (5.0y) ago | $59.61 | $1,795.17 | +79.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYMR forecast.
Our base-case forecast reaches $210.00 around 2030.
Implied market cap at $210.00: $17.27B
The forecast shows a rising long-term trajectory. In 2026 the avg price is $110.34 and the max is $145.24, with a neutral sentiment; by 2027 the avg rises to $135.89 and the max to $184.09 with a bullish stance and a 23.1% ROI. The path continues upward with 2028 avg $159.33, 2029 avg $184.24, and 2030 avg $231.94 with a 110.2% ROI and bullish sentiment.
By 2031 the avg is $291.70, 2032 $354.75, 2033 $377.95, 2034 $388.60, and 2035 $446.33, all labeled bullish. The forecast extends to 2040 with an avg of $829.63 and a 651.9% ROI, and to 2050 with an avg of $1,511.73 and a 1,270.1% ROI. These numbers depict a strong, long-run upside but remain estimates rather than guarantees, and they reflect high volatility (annualized volatility of 60%).
The assets’ multi-year trajectory assumes continued demand for targeted degradation therapies and favorable regulatory outcomes, but inherent clinical and market uncertainties mean outcomes can differ from these projections.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $231.94 with a max of $348.35 and a min of $167.10, and the ROI is 110.2% with a bullish sentiment.
The forecast shows a bullish sentiment from 2027 onward, with rising average prices (e.g., $135.89 in 2027, $159.33 in 2028, $184.24 in 2029, and $231.94 in 2030) and meaningful upside potential (e.g., ROI of 110.2% in 2030 and higher in later years). 2026 is neutral with an average price equal to the current price.
Yes. The forecast includes higher-price scenarios, with 2040 max at $1,473.74 and 2050 max at $2,965.78, indicating potential above $500 in the longer term.
The current price is $110.34 and the market cap is $9.08B.
The 30-day range is $89.46 to $136.09. Nearby technical levels are support at $76.91 and resistance at $119.35.
Kymera Therapeutics, Inc. Community Discussion
0Share your Kymera Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.